# Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

> **NCT05751798** · PHASE1,PHASE2 · RECRUITING · sponsor: **OSE Immunotherapeutics** · enrollment: 41 (estimated)

## Conditions studied

- Solid Advanced Tumor
- Lymphoma
- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** Part A: OSE-279 100mg
- **DRUG:** Part A: OSE-279 300mg
- **DRUG:** Part A: OSE-279 600mg
- **DRUG:** Part B: OSE-279 600 mg and OSE2101
- **DRUG:** Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive
- **DRUG:** Part C: OSE-279 600 mg - HLA-A2 positif
- **DRUG:** Part C: OSE-279 600 mg - HLA-A2 negative

## Key facts

- **NCT ID:** NCT05751798
- **Lead sponsor:** OSE Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-20
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751798, "Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05751798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*